drugset / Trial / NCT01010152

Comparative Bioavailability Study of Codeine Sulfate

NCT01010152

Phase 1 Completed 34 enrolled Roxane Laboratories
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study was to assess the comparative bioavailability of codeine from Roxane Laboratories' Codeine Sulfate 30mg tablets to Tylenol® #3 (acetaminophen 300mg with codeine phosphate 30mg) under fasted conditions

Timeline

Start
2008-01
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Codeine Small molecule 30 mg

Indications

No indication recorded.